Ghrelin and GH secretagogues, including GH-releasing peptide (GHRP)-6, stimulate food intake and adiposity. Because insulin modulates the hypothalamic response to GH secretagogues and acts synergistically with ghrelin on lipogenesis in vitro, we analyzed whether insulin plays a role in the metabolic effects of GHRP-6 in vivo. Streptozotocin-induced diabetic rats received saline, GHRP-6, insulin, or insulin plus GHRP-6 once daily for 8 wk. Rats receiving saline suffered hyperglycemia, hyperphagia, polydipsia, and weight loss. Insulin, but not GHRP-6, improved these parameters (P < 0.001 for all), as well as the diabetes-induced increase in hypothalamic mRNA levels of neuropeptide Y and agouti-related peptide and decrease in proopiomelanocortin. Cocaine amphetamine-related transcript mRNA levels were also reduced in diabetic rats, with GHRP-6 inducing a further decrease (P < 0.03) and insulin an increase. Diabetic rats receiving insulin plus GHRP-6 gained more weight and had increased epididymal fat mass and serum leptin levels compared with all other groups (P < 0.001). In epididymal adipose tissue, diabetic rats injected with saline had smaller adipocytes (P < 0.001), decreased fatty acid synthase (FAS; P < 0.001), and glucose transporter-4 (P < 0.001) and increased hormone sensitive lipase (P < 0.001) and proliferator-activated receptor-gamma mRNA levels (P < 0.01). Insulin normalized these parameters to control values. GHRP-6 treatment increased FAS and glucose transporter-4 gene expression and potentiated insulin's effect on epididymal fat mass, adipocyte size (P < 0.001), FAS (P < 0.001), and glucose transporter-4 (P < 0.05). In conclusion, GHRP-6 and insulin exert an additive effect on weight gain and visceral fat mass accrual in diabetic rats, indicating that some of GHRP-6's metabolic effects depend on the insulin/glucose status.
Also, as we age, our metabolic processes slow down, leading to less background energy consumption. Less exercise promoting muscular strength gets exchanged for walking and taking the stairs. This reduces muscle that burns fat and increases the metabolism again causing fat storage due to lack of activity. The result is obesity, which is now a pandemic.

Note: If you are a person concerned about loss of muscle mass, you can consume a small amount of protein every 2-3 hours (amino acid tablets such as EAA and BCAA are good for this purpose and can be purchased from any health food shop or ordered online). However there is little reason to be concerned about muscle loss because when fat is available for energy, such as following HGH Frag 176-191 injections, protein and therefore muscle mass are spared.
An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.
The simple science of amino acids linked together, via peptide bonds, brings to life this now common word – “Peptides”. Used for a variety of health, fitness and anti ageing concerns, Peptides can help in many ways to promote fat loss, build lean muscle, assist with injury recovery, increase agility, and many other anti ageing benefits. Peptides are amino acid chains that act as messengers in the cellular world by telling your cells what to do. One of the world’s best kept secrets for optimal health is Human Growth Hormone (HGH). HGH is so instrumentally important that its decline as we age is directly related to our health and quality of life. Modern medicine is now recognising its decrease as a clinical syndrome called “Growth Hormone Deficiency Syndrome”. By stimulating your Growth Hormone levels back to a level that is clinically predicted for your age will allow your body to perform at its peak which allows you to feel youthful and rejuvenated.
The second long-term study (METAOD006) was a randomized, double-blind, placebo-controlled, multi-center, parallel group study conducted at 16 Australian hospitals and medical centres. In that study 534 were enrolled but of those 502 clinically obese subjects (BMI ≥ 30 kg/m2 and ≤ 45 kg/m2; Median BMI: 36.3 kg/m2, range: 30 to 45.2 kg/m2; 44% males and 56% females) were randomized to receive a daily dose of 0.25, 0.5 or 1mg AOD9604 or placebo for 24 weeks. Prior to this treatment period all subjects underwent a 4-week single-blind placebo run-in period. After cessation of the treatment a 4-week follow-up phase was performed.
The scheduling of paracetamol and caffeine when combined in a compound analgesic as the only two active ingredients was amended from Schedule 4 to Schedule 2 by the NDPSC at its 50th Meeting in June 2007. Evidence reviewed by the Committee at that time conclusively demonstrated that the key ingredient in terms of analgesic overuse and nephropathy was phenacetin and not caffeine. It was agreed that the indications for use, safety profile and potential for misuse met the criteria for a Schedule 2 medicine.
Five public submissions were received. Many of the submissions referred to the article published in the New England Journal of Medicine (NEJM) when giving their reasons for either supporting or rejecting the proposal. Some submissions also noted that a similar proposal is to be considered by an upcoming meeting of the Medicines Classification Committee (MCC) in New Zealand.
A total of 97 AEs were reported by 17/17 subjects during this study. Most of them were of mild or moderate in intensity, with the exception of two SAEs, one of which (diarrhoea) was deemed “possibly related” to study treatment (54 mg AOD9604) and one (bronchial pneumonia) deemed to be “unrelated” to the study treatment (54 mg AOD9604). The most common adverse event reported was mild or moderate headache followed by events related to the digestive system, specifically diarrhea, flatulence, increased appetite and nausea. There was no observable trend between the AOD9604 groups or the placebo with respect to the incidence. The only event deemed definitely related to the treatment was taste perversion occurring 10 minutes following dose administration of the placebo.
In a statement to Fairfax Media on Thursday, Calzada Ltd said: ''The US generally recognised as safe 'GRAS' status is being explored as another viable commercial path for the company to pursue to potentially derive early revenue. Whilst AOD-9604 was not successful in human trials aimed at obesity, the Company believes there is sufficient efficacy data to enable a potential food, drink or dietary supplement product to be successfully marketed in the US.''
MGF stands for mechano growth factor—a peptide derived from insulin-like growth factor-1 (IGF-1), which plays a large role in childhood development and continues to have anabolic effects throughout adulthood. MGF has the ability to encourage repair and growth of wasted tissue through the activation of muscle stem cells, thereby increasing the synthesis of proteins necessary for tissue growth. This peptide is ideal of anyone suffering from muscle loss, either due to old age or a particular condition (i.e., HIV, cancer, etc.)

AOD9604 and hGH appear to act in a similar manner to induce their effects on body weight regulation and adipose tissue mass in vivo. However, in vitro studies have demonstrated a number of differences suggesting that the two compounds operate via unique signaling pathways to control the regulation of theβ 3-AR. These studies suggested that AOD9604 had no interaction with the β3-AR or hGH receptors (11).


We at Muscle Peptides Australia specialise in providing customers with the highest quality peptide supplements that can enable them to unlock their body’s full potential. Operating out of Melbourne and headed by a team of experienced anti-ageing doctors, we offer our customers a no-obligation online assessment. Customers can make enquiries by e-mailing info@musclepeptides.com.au and have their questions answered by the company’s doctor, you can request information about everything from supplements to fitness, muscle building, anti-aging and weight loss.
×